Dean Ht Elbe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1779057/publications.pdf

Version: 2024-02-01

		1040056	752698
36	409	9	20
papers	citations	h-index	g-index
26	26	36	F10
36	36	36	510
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Bupropion-Induced Serum Sickness–Like Reaction. Annals of Pharmacotherapy, 2000, 34, 471-473.	1.9	72
2	First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2010, 19, 124-37.	0.6	51
3	Focus on aripiprazole: a review of its use in child and adolescent psychiatry. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2009, 18, 250-60.	0.6	46
4	Update on the Use of SSRIs and SNRIs with Children and Adolescents in Clinical Practice. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2016, 25, 4-10.	0.6	35
5	Review of the pharmacotherapy of irritability of autism. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2012, 21, 130-46.	0.6	25
6	Therapeutic Drug Levels of Second Generation Antipsychotics in Youth: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 234-245.	1.3	24
7	Moxifloxacinâ€"Warfarin Interaction: A Series of Five Case Reports. Annals of Pharmacotherapy, 2005, 39, 361-364.	1.9	22
8	Prevalence and Patterns of Antipsychotic Use in Youth at the Time of Admission and Discharge From an Inpatient Psychiatric Facility. Journal of Clinical Psychopharmacology, 2014, 34, 17-22.	1.4	18
9	Focus on ziprasidone: a review of its use in child and adolescent psychiatry. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2008, 17, 220-9.	0.6	13
10	Pathways to Overmedication and Polypharmacy. , 2015, , 125-148.		12
11	Sleep as an outcome measure in ADHD randomized controlled trials: A scoping review. Sleep Medicine Reviews, 2022, 63, 101613.	8.5	10
12	Lifesaving Electroconvulsive Therapy for a Child With Autism Spectrum Disorder, Severe Self-Injurious Behavior, and Neuroleptic Malignant Syndrome. Journal of ECT, 2019, 35, e55-e56.	0.6	8
13	A retrospective study of antipsychotic drug switching in a pediatric population. BMC Psychiatry, 2013, 13, 248.	2.6	7
14	Stimulant â€~rapid metabolizers': wrong label, real phenomena. ADHD Attention Deficit and Hyperactivity Disorders, 2018, 10, 113-118.	1.7	7
15	Management of Acute Agitation and Aggression in Children and Adolescents with Pro Re Nata Oral Immediate Release Antipsychotics in the Pediatric Emergency Department. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 534-541.	1.3	7
16	Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2010, 19, 303-14.	0.6	7
17	Focus on Guanfacine Extended-release: A Review of its Use in Child and Adolescent Psychiatry. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2014, 23, 48-60.	0.6	6
18	Manic Reaction in a Child Induced by Guanfacine-Extended Release. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 566-567.	1.3	5

#	Article	IF	CITATIONS
19	A review of escitalopram and citalopram in child and adolescent depression. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2011, 20, 315-24.	0.6	5
20	How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2010, 19, 40-5.	0.6	4
21	Do Hospital and Community SSRI Usage Patterns in Children and Adolescents Match the Evidence?. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2010, 19, 218-26.	0.6	4
22	Retrospective Review of Fluvoxamine-Clomipramine Combination Therapy in Obsessive-Compulsive Disorder in Children and Adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2021, 30, 150-155.	0.6	4
23	Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment. Journal of Psychiatry and Neuroscience, 2014, 39, E32-E33.	2.4	3
24	The role of pharmacotherapy in the management of self-regulation difficulties in young children. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2009, 18, 150-9.	0.6	3
25	Do We Know If They Work and If They Are Safe. , 2015, , 27-64.		2
26	Formal Psychiatry Resident Rotations with a Clinical Pharmacy Specialist: Preliminary Experience at BC Children's Hospital. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2019, 28, 7-8.	0.6	2
27	Retrospective Review of Clozapine Use in Children and Adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2021, 30, 36-48.	0.6	2
28	Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive–compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study. BMJ Open, 2022, 12, e054296.	1.9	2
29	Lack of Detectable Serum Levels Following Topical Fluoxetine Administration in a Child. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 105-106.	1.3	1
30	Commentary to QTc prolongation associated with atypical antipsychotic use in the treatment of adolescent-onset anorexia nervosa. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2009, 18, 64.	0.6	1
31	Psychiatric Manifestations in Patients with Biopterin Defects. Neuropediatrics, 2022, 53, 176-181.	0.6	1
32	Review: evidence on the comparative effectiveness and adverse effects of antipsychotics in young people is limited. Evidence-Based Mental Health, 2012, 15, 79-79.	4.5	0
33	ISDN2014_0424: Challenging/disruptive sleep/wake behaviours in adolescents with fetal alcohol spectrum disorders: latrogenic effects of prescription medications. International Journal of Developmental Neuroscience, 2015, 47, 128-128.	1.6	0
34	Switching from Clonidine Immediate-Release to Guanfacine Extended-Release. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2020, 29, 121-123.	0.6	0
35	Psychopharmacology Challenge. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2020, 29, 202-208.	0.6	0
36	Response to "". Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2021, 30, 278-279.	0.6	0